CN102026672A - C2orf18作为癌症治疗和诊断的靶基因 - Google Patents

C2orf18作为癌症治疗和诊断的靶基因 Download PDF

Info

Publication number
CN102026672A
CN102026672A CN2009801171940A CN200980117194A CN102026672A CN 102026672 A CN102026672 A CN 102026672A CN 2009801171940 A CN2009801171940 A CN 2009801171940A CN 200980117194 A CN200980117194 A CN 200980117194A CN 102026672 A CN102026672 A CN 102026672A
Authority
CN
China
Prior art keywords
c2orf18
polypeptide
gene
cancer
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801171940A
Other languages
English (en)
Chinese (zh)
Inventor
中村佑辅
中川英刀
中鹤修一
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of CN102026672A publication Critical patent/CN102026672A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
CN2009801171940A 2008-03-12 2009-03-10 C2orf18作为癌症治疗和诊断的靶基因 Pending CN102026672A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3603508P 2008-03-12 2008-03-12
US61/036,035 2008-03-12
PCT/JP2009/001057 WO2009113295A1 (en) 2008-03-12 2009-03-10 C2orf18 as target gene for cancer therapy and diagnosis

Publications (1)

Publication Number Publication Date
CN102026672A true CN102026672A (zh) 2011-04-20

Family

ID=41064968

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801171940A Pending CN102026672A (zh) 2008-03-12 2009-03-10 C2orf18作为癌症治疗和诊断的靶基因

Country Status (9)

Country Link
US (1) US20110098339A1 (enExample)
EP (1) EP2262541A4 (enExample)
JP (1) JP2011518541A (enExample)
KR (1) KR20100128326A (enExample)
CN (1) CN102026672A (enExample)
BR (1) BRPI0909310A2 (enExample)
CA (1) CA2718382A1 (enExample)
RU (1) RU2010141742A (enExample)
WO (1) WO2009113295A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101406314B1 (ko) * 2011-07-19 2014-06-12 연세대학교 산학협력단 췌장암 암 줄기세포 특성에 기초한 췌장암의 치료용 타겟
CN116794325B (zh) * 2023-06-15 2024-05-10 中山大学 敲低或抑制slc35f6的试剂在制备激活ampk的药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006110593A2 (en) * 2005-04-07 2006-10-19 Macrogenics, Inc. Biological targets for the diagnosis, treatment and prevention of cancer
KR20070101610A (ko) * 2006-04-11 2007-10-17 주식회사 바이오인프라 Ａｎｔ２ 유전자의 발현을 억제하는 작은 간섭 ｒｎａ를이용한 암 유전자 치료 및 항암제 내성 극복방법

Also Published As

Publication number Publication date
EP2262541A4 (en) 2012-02-29
US20110098339A1 (en) 2011-04-28
JP2011518541A (ja) 2011-06-30
BRPI0909310A2 (pt) 2017-06-27
KR20100128326A (ko) 2010-12-07
CA2718382A1 (en) 2009-09-17
RU2010141742A (ru) 2012-04-20
EP2262541A1 (en) 2010-12-22
WO2009113295A1 (en) 2009-09-17

Similar Documents

Publication Publication Date Title
JP5764822B2 (ja) がんの治療および診断の標的遺伝子としてのｐｒｍｔ１
JP2010536366A (ja) 肺癌の治療及び診断の標的遺伝子のためのｅｂｉ３、ｄｌｘ５、ｎｐｔｘ１、及びｃｄｋｎ３
CN101835893A (zh) 癌症相关基因cdca5、epha7、stk31和wdhd1
JP2012509058A (ja) 前立腺癌を診断または治療するための方法
JP2010512730A (ja) 肺癌の腫瘍マーカーおよび治療標的としてのｔｔｋ
CN101855346A (zh) Pkib和naaladl2用作前列腺癌治疗和诊断的靶基因
US20090215683A1 (en) Screening and therapeutic method for nsclc targeting cdca1-kntc2 complex
JP2012501167A (ja) 膵臓癌関連遺伝子ｔｔｌｌ４
CN102026672A (zh) C2orf18作为癌症治疗和诊断的靶基因
US20110070245A1 (en) Imp-1 oncogene as a therapeutic target and prognostic indicator for lung cancer
JP2012501163A (ja) がんの治療および診断用の標的遺伝子としてのｃ１２ｏｒｆ４８
WO2010023838A1 (en) Tbc1d7 as tumor marker and therapeutic target for cancer
KR20110063490A (ko) 암 치료 및 진단의 표적 유전자인 ｓｙｎｇｒ４
WO2012023290A1 (en) Rasef as tumor marker and therapeutic target for cancer
JP2012501166A (ja) 乳癌関連遺伝子ｒｑｃｄ１
JP2012501162A (ja) 癌の治療および診断のための標的遺伝子としてのｏｉｐ５
WO2012153492A1 (en) Nptx2 as tumor marker and therapeutic target for cancer
JP2012501169A (ja) がん関連遺伝子ｌｇｎ／ｇｐｓｍ２
WO2012023288A1 (en) Fam161a as a target gene for cancer therapy and diagnosis
WO2012023259A1 (en) C6orf167 as a target gene for cancer therapy and diagnosis
CN102575300A (zh) 肺癌治疗和诊断的靶基因cstf2
JP2013501501A (ja) 腫瘍マーカーおよびがんの治療標的としてのｃｄｃ４５ｌ

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110420